

## Original Research Article

### **Genetic polymorphisms of MTRRA66G genes and susceptibility to Acute Lymphoblastic Leukemia in the Yemeni population**

#### **Abstract**

**Background:** Folic acid metabolism has a major role in DNA methylation and synthesis. Genetic Polymorphisms in folate may disrupt enzyme activities and maybe affect the malignant risk.

Methionine synthase reductase <MTRR> are very important enzyme for the folate cycle.

**Objectives:** to study the possible relation between polymorphisms of MTRRA66G genes and susceptibility to acute lymphoblastic leukemia (ALL) in Yemeni patients.

**Methods:** a total of 115 patients with ALL attended oncology centers in Yemen and 140 unrelated healthy individuals as a control group was involved in a case-control study. DNA was extracted from collected EDTA venous blood samples and analyzed by polymerase chain reaction-restriction fragment length polymorphism assay [PCR-RFLP].

**Results:** The frequency of MTRR 66A-G heterozygous(AG), homozygous (GG) and wild type (AA) in cases was 52.2%(60), 22.6%(26), and 25.2%(29), respectively. Whereas, the frequency of MTRR 66A-G heterozygous(AG), homozygous (GG) and wild type (AA) in controls was 46.4%(65), 27.1%(38), and 26.4%(37), respectively. The difference in frequencies were statistically insignificant ( $P=0.471$ , OR = 1.065, 95% confidence interval (CI) 0.606–1.873) .

**Conclusion:** Our finding for MTRR A66G polymorphism does not associate with the development of acute lymphoblastic leukemia in Yemeni patients.

**Keywords:** Acute lymphoblastic leukemia, methionine synthase reductase, polymorphism, Yemen.

## Introduction

Folic acid metabolism has a major role in DNA methylation and synthesis. Genetic Polymorphisms in folate may disrupt enzyme activities and maybe affect the malignant risk. methionine synthase reductase <MTRR> are very important enzyme for the folate cycle. (Amigou et al.(2012) <sup>[1]</sup>

The previous study shows the MTRR gene was associated with a significantly reduced risk of acute lymphoblastic leukemia ( $p = 1.21$ ,  $OR = 0.55$ ), which resulted mainly from the reduced risk of B-cell and hyperdiploid- acute lymphoblastic leukemia (Lautner-Csorba et al., 2013) <sup>[2]</sup>. MTRR polymorphisms (66A>G, 524C>T, 1049G>T, and 2756A>G) could theoretically reduce the risk to develop childhood acute lymphoblastic leukemia by inhibiting MTR, resulting in DNA hypomethylation and reducing the risk of the silencing of genes, like tumor suppressor genes, such as TP53 and others (Shah et al., 2001; Robien and Ulrich, 2003). <sup>[3-4]</sup> For both MTRR 66AG and MTRR 66GG, a Korean study carried out by (Kim et al., 2009) <sup>[5]</sup> found no significant difference in susceptibility to acute lymphoblastic leukemia. Gemmati et al., (2004) <sup>[6]</sup> evaluated whether four common polymorphisms in methylene tetrahydrofolate reductase (MTHFR677T and A1298C), methionine synthase (MSA2756G), and methionine synthase reductase (MTRRA66G) genes may have a role in altering susceptibility to adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma (NHL). Individuals carrying the MTHFR677TT and MTRR66AG genotypes revealed a 4.2-fold acute lymphoblastic leukemia risk reduction( $OR\ 0.24$ ,  $95\%\ CI\ 0.06 - 0.81$ ), whereas, those with the MS 2756AG/GG and MTRR66AG/GG genotypes revealed a 2.2-fold acute lymphoblastic leukemia risk reduction ( $OR\ 0.45$ ,  $95\%\ CI\ 0.10 - 0.85$ ).

Petra et al.(2007) analyzed common genetic polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS), methionine synthase (MS), and methionine synthase reductase (MTRR) in 68 children with acute lymphoblastic leukemia and 258 healthy controls to investigate their influence on the risk for acute lymphoblastic leukemia. They found no significant differences in frequencies of separate polymorphisms observed between both groups. Combined MTHFR 677CT/TT and MS 2756AG/GG genotypes showed a nonsignificant tendency to reduce the risk for acute lymphoblastic leukemia 2.24-fold ( $CI: 0.191 - 1.037$ ,  $P: 0.061$ ). The risk was significantly reduced in carriers of

combined MTHFR 677CT/TT, MS 2756AG/GG, and MTRR 66AG/GG genotypes (OR: 0.312; CI: 0.107 – 0.907; *P*: 0.032). They suggested that gene-gene interactions may decrease the methylation capacity which may have a protective effect on the risk for childhood acute lymphoblastic leukemia.<sup>[7]</sup>

Gra et al. (2008a) studied genetic polymorphism of *GST*, *NAT2*, and *MTRR* and susceptibility to childhood acute leukemia in Russia. The frequency of *MTRR* genotype 66G/G was reduced in girls with acute leukemia as compared to healthy female donors (OR = 0.50, *P* = 0.0015). The *GSTT1* and/or *GSTM1* null genotypes combined with *MTRR* genotype 66A/G were considered to be a risk factor for acute leukemia in girls. Thus, the polymorphisms of *GSTT1*, *GSTM1*, *NAT2*, and *MTRR* proved to influence the risk of childhood acute leukemia in residents of European.<sup>[8]</sup>

In the study performed by Koppen et al. (2010) on the folate-related gene polymorphisms (*MTRR*, *MTR*[MS]) and susceptibility to develop childhood acute lymphoblastic leukemia, there is less clearly an association between these gene polymorphisms with susceptibility to acute lymphoblastic leukemia.<sup>[9]</sup> Also, folate-related gene polymorphisms associated with the risk of childhood leukemia were studied by Wagiman et al. (2011) in the Malaysian population. They found *MTRR* 66 GG variant was associated with reduced risk of developing childhood leukaemia (OR = 0.05; 95 % CI, 0.01-0.29; *p* < 0.001).<sup>[10]</sup>

Amigou et al. (2012) studied the effect of folic acid supplementation, MTHFR, and MTRR polymorphisms, and the risk of childhood leukemia. They revealed that MTHFR and MTRR genetic polymorphisms were not associated with acute lymphoblastic leukemia.<sup>[11]</sup>

Fang et al. (2014) investigated the association between methionine synthase reductase A66G polymorphism and leukemia risk in their meta-analysis study. No significant associations were found for all comparisons in the overall pooled analysis. The results of stratified analyses revealed that *the MTRR* A66G GG genotype was associated with decreased leukemia risk in the Caucasian population, in children, and for acute lymphoblastic leukemia. In contrast, the increased risk was observed in the Asian population and for acute myeloid leukemia (AML). They suggested that *MTRR* A66G

GG is associated with decreased risk of leukemia in a Caucasian population and children, especially for acute lymphoblastic leukemia. <sup>[11]</sup>

Wang et al.(2017) performed a meta-analysis up to October 2016 to investigate the association of MTRRA66G polymorphism and cancer susceptibility and suggested that, the MTRR A66G polymorphism is associated with significantly increased cancer risk. <sup>[12]</sup>

## **Materials and methods**

### ***Study population***

This study was conducted on 115 Patients attending the oncology centers who were diagnosed with ALL in the period from 2015- 2018 were invited to take part in the study and sign an informed consent and 140 healthy controls matched to the cases in gender and age.

The study includes all Yemeni patients who have confirmed diagnosis of ALL, at any age, of both sexes, and from different areas, who attended oncology centers during the study period. The control group was of healthy individuals who matched to patients in gender and age.

### ***DNA extraction***

DNA was extracted from EDTA blood samples using a DNA purification kit (G-spin TM Total DNA extraction kit protocol intron biotechnology). DNA was quantified by nanodrop and stored at -20 c.


Comment [C1]: PLEASE CORRECT °C

### **Genotyping of MTRR gene(66A-G) polymorphism**

MTRR gene(66A-G)polymorphism was determined with a polymerase chain reaction-restriction fragment length polymorphism assay [PCR-RFLP]. PCR primers were: 5'-GCA AAG GCC ATC GCA GAA GAC AT-3'(F) and 5'-GTG AAG ATC TGC AGA AAA TCCATG TA3'(R). PCR was carried out in a total volume of 20 µl, consist 1µl of genomic DNA, 1µl of each primer, ready-to-load master mix (Maxime TM premix kit (i-Taq), and 17µl distilled water. PCR condition was initial denaturation at 95°C for 3 minutes, followed by 30 cycles at 94°C for 30 seconds, 60.5°C for 30 seconds, 72°C for 50 seconds, and the last extension at 72°C for 10 minutes. PCR products were analyzed on a 2% agarose gel stained with 0.3 µg/mL ethidium bromide, and visualized by a gel documentation system (to check the presence of 66 pb of MTRR).


Then the PCR product was digested with the restriction endonuclease (Nde I) restriction enzyme {VIVANTIS product No RE1266} as follows: For each 5  $\mu$ l of PCR product, 2  $\mu$ l from 10X buffer V5 and 2  $\mu$ l from (Nde I) restriction enzyme (1:10 stock enzyme to diluent A) and 3  $\mu$ l of distal water were added, then incubated at 37°C for 24 hrs, followed by incubation at 65°C for 10 minutes to inhibit the enzyme activity. The products are then resolved on 4% agarose gel electrophoresis containing ethidium bromide, then visualized using UV trans illuminator. The amplified fragment after digestion with (Nde I) restriction enzyme, will give rise to 2 fragments at 44 bp and 22 bp indicating the presence of the A (isoleucine) allele but the PCR fragment of 66bp remains uncut in the presence of the G (methionine) allele.

**Comment [C2]:** LACK OF SPACE



**Fig1.** PCR product of MTRR gene.

M, 50 bp ladder molecular weight marker .lane 1-5, 66 bp PCR product.



**Fig2.MTRR A66G polymorphism digested by NdeI restriction enzyme.**

M, 50 bp ladder molecular weight marker. wild type (66AA ,44,22), homozygous type (66GG ,66 bp un cut), heterozygous type (66 AG ,66, 44 and 22 bp)

#### **Statistical Analysis**

Demographic data were analyzed to obtain the mean, the standard deviation, and the probability (P value) between patients and the control group using the Statistical Packages of Social Science (SPSS) software program version 16. The Pearson's chi-square test was used to compare the genotype distribution between patients and control. P-values less than 0.05 were considered as statistically significant. Odds ratios were estimated for each variable. Logistic regression analysis was used to estimate the risk of developing ALL according to demographic data. P value of <0.05 was considered significant

#### **Results**

##### **MTRRA66G genotypes in Yemeni acute lymphoblastic leukemic patients and controls**

The frequency of MTRR 66A-G heterozygous(AG), homozygous (GG) and wild type (AA) in cases was 52.2%(60), 22.6%(26) and 25.2%(29), respectively. Whereas, the frequency of MTRR 66A-G heterozygous(AG), homozygous (GG) and wild type (AA) in controls was 46.4%(65), 27.1%(38), and 26.4%(37), respectively. The difference in frequencies were statistically insignificant (P=0.471, OR = 1.065, 95% confidence interval (CI) 0.606–1.873) (Table 1).

**Table 1. MTRRA66G genotypes in Yemeni acute lymphoblastic leukemic patients and controls**

Gene	Genotype	Cases N=115	Control N=140	P value	OR	95%CI	
						Lower	upper
MTRR	AG	60(52.2%)	65(46.4%)	0.471	1.065	0.606	1.873
	GG	26(22.6%)	38(27.1%)				
	AA	29(25.2%)	37(26.4%)				

**Relationship between MTRRA66G genotypes and risk factors in acute lymphoblastic leukemia patients.**

The presence of MTRRA66G mutant genotypes showed a trend towards radiation, negative smoking, and infection showing an OR (95% CI) of 1.776(0.366-8.627), 1.147 (0.282-1.934), and 1.283(0.433-3.043) respectively. However, the association is not statistically significant (Table2).

Comment [C3]: LACK OF SPACE

**Table 2. Relationship between MTRRA66G genotypes and risk factors in acute lymphoblastic leukemia patients.**

Risk factors	MTRRA66G genotype (N=115)			P value
	AG	GG	AA	
Family history	Yes	10	2	0.526
	No	50	22	
Radiation	Yes	6	4	0.781
	No	54	27	
Smoking	Yes	5	2	0.459
	No	55	25	
Negative smoking	Yes	15	8	0.982
	No	45	22	
Infection	Yes	31	13	0.267
	No	29	10	

**Table 3. Relationship between MTRRA66G genotypes and risk factors in acute lymphoblastic leukemia patients.**

Risk factors		MTRRA66G genotype (N=115)		OR	Lower	Upper	P value
		mutant	non mutant				
Family history	Yes	12	7	0.510	0.179	1.452	0.161
	NO	74	22				
Radiation	Yes	10	2	1.776	0.366	8.627	0.373
	NO	76	27				
Smoking	Yes	7	4	0.554	0.150	2.049	0.286
	NO	79	25				
Negative smoking	Yes	23	7	1.147	0.282	1.934	0.351
	NO	63	22				
Infection	Yes	44	19	1.283	0.433	3.043	0.495

## Discussion

Acute lymphoblastic leukemia is the most common cancer seen in children (Hanson and Mulvihill, 1980; Gurney et al., 1996).<sup>[13-14]</sup> This study is performed to detect if there is an association between polymorphism in MTRR gene and Acute lymphoblastic leukemia in the Yemeni population. A total number of 1522 cases of leukemia were evaluated over 5 years from June 2010 to December 2014. Previous studies indicated that ALL is the second most common adult leukemia in Yemen.<sup>[15-17]</sup> Exogenous and Endogenous toxins may lead to alterations inside different genes, which may increase susceptibility to cancer development, like ALL (Wogan et al., 2004).<sup>[18]</sup>

There was little knowledge of MTRR gene polymorphisms, therefore we studied this gene because the gene is important for catalytic interaction with folate, homocysteine, and cobalamin during embryogenesis (Wilson et al., 1999; Brouns et al., 2008; Barbosa et al., 2008).<sup>[19-21]</sup> Methionin synthase enzyme (MTR) encoded by the MTR gene, uses the methyl group from methyltetrahydrofolate for remethylation of homocystiene to methionine (Brugada and Marian, 1997).<sup>[22]</sup> The MTRR is essential

Comment [C4]: LACK OF SPACE

Comment [C5]: •IMPROVE YOUR WRITING

for the maintenance of MTR functions and is one of the key regulatory enzymes involved in the folate pathway(Wang et al., 2013).<sup>[23]</sup>

Comment [C6]: space

There was no previous study on the prevalence of MTRR 66A-G polymorphisms and their association with acute lymphoblastic leukemic patients in Yemen. In the present study, we investigate ALL patients to identify associations with MTRR A66G polymorphisms compared with control. The results showed that the frequency of MTRR 66A-G heterozygous (AG), homozygous(GG), and wild type(AA) were 52.2%(60), 22.6%(26), and 25.2%(29), respectively in cases. In contrast, there were 46.4%(65) of control people with heterozygous (AG) type, 27.1%(38) with homozygous (GG), and 26.4%(37) with wild type(AA). The difference in frequencies were statistically insignificant ( $P=0.471$ ,  $OR = 1.065$ , 95% confidence interval (CI) 0.606–1.873). Our finding for MTRR A66G polymorphism does not associate with the development of acute lymphoblastic leukemia in Yemeni patients. This results agree with previous study done by Wagiman et al.(2011)<sup>[10]</sup> in Malaysian population were MTRR66GG variant ( $OR = 0.05$ , 95% confidence interval (CI) 0.01–0.29), (Lautner-Csorba et al., 2013) ( $P$  value=1.21).<sup>[2]</sup> In Korean study found no significant difference in susceptibility to ALL(Kim et al., 2009).<sup>[5]</sup> Another German study found a decrease in susceptibility to leukemia for MTRR genes heterozygous (AG) and homozygous (GG)(Gast et al., 2007).<sup>[24]</sup> Similarly, our results agreed with the meta-analysis study done by Fang et al.(2014)<sup>[11]</sup> performed for 2913 cases and 4764 controls. MTRR mutant genotype showed a trend toward the development of infections, however, the association is not statistically significant. Similar results were obtained in Filipino children(Grace, 2016).<sup>[25]</sup>

Comment [C7]: space

Comment [C8]: another study in german population found... review your sentences

Conclusion: This study concluded there is no significant association between the MTRR A66G polymorphism and acute lymphoblastic leukemia in Yemeni patients..

## Referances

1. AMIGOU, A., RUDANT, J., ORSI, L., GOUJON-BELLE, S., LEVERGER, G., BARUCHEL, A., BERTRAND, Y., NELKEN, B., PLAT, G. & MICHEL, G. 2012. Folic acid supplementation, MTHFR and MTRR polymorphisms, and the risk of childhood leukemia: the ESCALE study (SFCE). *Cancer Causes & Control*, 23, 1265-1277.

2. LAUTNER-CSORBA, O., GÉZSI, A., ERDÉLYI, D. J., HULLÁM, G., ANTAL, P., SEMSEI, Á. F., KUTSZEI, N., KOVÁCS, G., FALUS, A. & SZALAI, C. 2013. Roles of genetic polymorphisms in the folate pathway in childhood acute lymphoblastic leukemia evaluated by Bayesian relevance and effect size analysis. *PLoS one*, 8, e69843. *Biochemistry*, 43, 1988-1997.
3. SHAH, S. J., TAUB, J. W., WITT, T. L., POLLOCK, B. H., DING, B. C., MOORE, D. S., AMYLN, M., PULLEN, J., RAVINDRANATH, Y. & MATHERLY, L. H. 2001. Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukaemia. *British Journal of Haematology*, 113, 746-756.
4. ROBIEN, K. & ULRICH, C. M. 2003. 5, 10-Methylenetetrahydrofolate reductase polymorphisms, and leukemia risk: a HuGE minireview. *American journal of epidemiology*, 157, 571-582.
5. KIM, H. N., KIM, Y.-K., LEE, I.-K., YANG, D.-H., LEE, J.-J., SHIN, M.-H., PARK, K.-S., CHOI, J.-S., PARK, M. R. & JO, D. Y. 2009. Association between polymorphisms of folate-metabolizing enzymes and hematological malignancies. *Leukemia Research*, 33, 82-87.
6. GEMMATI, D., ONGARO, A., SCAPOLI, G. L., DELLA PORTA, M., TOGNAZZO, S., SERINO, M. L., DI BONA, E., RODEGHIERO, F., GILLI, G. & REVERBERI, R. 2004. Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. *Cancer Epidemiology and Prevention Biomarkers*, 13, 787-794.
7. PETRA, B. G., JANEZ, J. & VITA, D. 2007. Gene-gene interactions in the folate metabolic pathway influence the risk for acute lymphoblastic leukemia in children. *Leukemia & Lymphoma*, 48, 786-792.
8. GRA, O., GLOTOV, A., KOZHEKBAYEVA, Z. M., MAKAROVA, O. & NASEDKINA, T. 2008a. Genetic polymorphism of GST, NAT2, and MTRR and susceptibility to childhood acute leukemia. *Molecular Biology*, 42, 187.
9. KOPPEN, I. J., HERMANS, F. J. & KASPERS, G. J. 2010. Folate-related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukemia. *British Journal of Haematology*, 148, 3-14.
10. WAGIMAN, S. N., HUSIN, N. H., LATIFF, Z. A., ALIAS, H., JAMAL, R. & ZAKARIA, S. Z. S. 2011. Folate-related genes polymorphisms are associated with the risk of childhood leukaemia in the Malaysian population. *Asia-Pacific Journal of Molecular Medicine*, 1, 7.
11. FANG, D.-H., JI, Q., FAN, C.-H., AN, Q. & LI, J. 2014. Methionine synthase reductase A66G polymorphism and leukemia risk: evidence from published studies. *Leukemia & Lymphoma*, 55, 1910-1914.
12. WANG, P., LI, S., WANG, M., HE, J. & XI, S. 2017. Association of MTRR A66G polymorphism with cancer susceptibility: Evidence from 85 studies. *Journal of Cancer*, 8, 266.
13. HANSON, M. & MULVIHILL, J. 1980. Epidemiology of child-blood cancer In Levine AS, *Cancer in the Young*. New York: Masson.
14. GURNEY, J. G., DAVIS, S., SEVERSON, R. K., FANG, J. Y., ROSS, J. A. & ROBISON, L. L. 1996. Trends in cancer incidence among children in the US. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 78, 532-541.

15. Radfan Hassan, Hussein Musa, Gamal Abdul Hamid et al ; .Epidemiological study in acute lymphoblastic leukemia in Yemen .European Journal of Pharmaceutical Sciences • September 2017
16. Abdul Hamid G, (2015).clinicoepidemiological features of Adult leukemias in Aden, Yemen volume 5 /issue 7/ p334 Indian journal of applied research.
17. Hamid GA. The pattern of hematological malignancies at Al-Gamhouria teaching hospital, Aden, Yemen, from 2008 to 2010. Turk J Hematol. 2012;29:342–7.
18. WOGAN, G. N., HECHT, S. S., FELTON, J. S., CONNEY, A. H. & LOEB, L. A. Environmental and chemical carcinogenesis. Seminars in cancer biology, 2004. Elsevier, 473-486.
19. WILSON, A., PLATT, R., WU, Q., LECLERC, D., CHRISTENSEN, B., YANG, H., GRAVEL, R. A. & ROZEN, R. 1999. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B 12) increases the risk for spina bifida. *Molecular Genetics and Metabolism*, 67, 317-323.
20. BROUNS, R., URSEM, N., LINDEMANS, J., HOP, W., PLUIJM, S., STEEGERS, STEEGERS-THEUNISSEN, R. 2008. Polymorphisms in genes related to folate and cobalamin metabolism and the associations with complex birth defects. *Prenatal diagnosis*, 28, 485-493.
21. BARBOSA, P., STABLER, S., MACHADO, A., BRAGA, R., HIRATA, R., HIRATA, M., SAMPAIO-NETO, L., ALLEN, R. & GUERRA-SHINOHARA, E. 2008. Association between decreased vitamin levels and MTHFR, MTR and MTRR gene polymorphisms as determinants for elevated total homocysteine concentrations in pregnant women. *European journal of clinical nutrition*, 62, 1010.
22. BRUGADA, R. & MARIAN, A. 1997. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. *Atherosclerosis*, 128, 107-112.
23. GAST, A., BERMEJO, J., FLOHR, T., STANULLA, M., BURWINKEL, B., SCHRAPPE, M., BARTRAM, C., HEMMINKI, K. & KUMAR, R. 2007. Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: a case–control study. *Leukemia*, 21, 320.
24. WANG, S. S., FENG, L., QIAO, F. Y. & LV, J. J. 2013. A functional variant in methionine synthase reductase decreases the risk of Down syndrome in China. *Journal of Obstetrics and Gynaecology Research*, 39, 511-515.
25. GRACE, D.-B. A. 2016. Association of glutathione-S-transferase M1, P1, and T1 gene polymorphisms with treatment response in childhood acute lymphocytic leukemia. *Acta Medica Philippina*, 50, 75-80.